|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, IL-32 was associated with tumor size and Dukes' stage.
|
30988822 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The inhibitory effects of IL-32γ on tumor development were associated with inhibition of the STAT5 pathway.
|
31263095 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Carcinogen-induced tumor incidence in IL-32γ mice was significantly reduced in comparison to that in WT mice.
|
30486830 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Downregulated expression of IL-32 in tumor tissue of patients with diffuse type of gastric cancer may implicate on its role in limiting ongoing proinflammatory and proangiogenic processes.
|
30402092 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Some IL-32 isoforms have been linked to disease outcome and were shown to positively influence tumor development and progression in various different malignancies, including gastric, breast and lung cancers.
|
29747940 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of IL-32 is regulated by numerous factors, including genetic variations, hypoxia and acidosis in the tumour microenvironment.
|
29930712 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In an in vivo carcinogen induced lung tumor model, tumor growth was inhibited in IL-32γ overexpressed mice with elevated TIMP-3 expression and hypomethylation accompanied with reduced NF-κB activity.
|
29467412 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our data suggest a possible survival mechanism by the splicing of IL-32γ to IL-32β and also IL-6, IL-8, and CXCR1 signaling pathways to reverse the proapoptotic effect of the IL-32γ isoform, leading to tumor cell survival and thus favoring tumor progression.
|
29037857 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Other studies suggested that IL-32 decreases tumor development including cervical cancer, colon cancer and prostate cancer, melanoma, pancreatic cancer, liver cancer and chronic myeloid leukemia.
|
28223235 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Hence, it can be concluded that IL-32θ is an anti-inflammatory cytokine that can act as a tumor suppressor and can play vital role in colon cancer therapies.
|
29218075 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL32 expression and Treg infiltration in ESCC play an important synergistic role in tumor growth and invasion.
|
25964580 |
2015 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The analysis revealed an interaction between IL8 -251A>T and IL32 rs28372698 SNPs among cases with moderately- or well-differentiated tumors.
|
24982364 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We showed that patients with tumor expressing high amounts of IL32 exhibit decreased disease-free periods (20.5 mo vs. 41 mo, P = 0.0041) and overall survival (P = 0.0359) in comparison with individuals with weak IL32 tumor expression.
|
23359495 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
IL-32 mRNA expression levels in lesional skin of MF patch, plaque, and tumor were increased compared with those of normal skin, which positively correlated with CCL17 and CCL18 mRNA expression levels.
|
24226419 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The proinflammatory cytokine interleukin-32 (IL-32) is a novel tumor marker highly expressed in various human carcinomas, including gastric cancer.
|
24602839 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor tissues isolated from LPS-injected mice inoculated with IL-32γ-overexpressing colon cancer cells potentiated the expression levels of pro-apoptotic proteins such as cleaved caspase-3, 9 and Bax, but decreased that of Bcl-2.
|
23255489 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Results demonstrate substantial IL-32 expression in TC tumor tissue.
|
23486016 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Multivariate analysis demonstrated that IL-32 is one of the prognostic markers (p < 0.03) for gastric cancer, in addition to nodal involvement and tumor depth.
|
23479179 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There is increase in p-p38MAPK activation underlying IL-32 expression in tumor P=0.004, but no change in total p38 MAPK in malignant esophagus.
|
23107826 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
By performing immunohistochemical assays on primary breast cancer samples, we found that the level of IL-32β expression was positively correlated with tumor size, number of lymph node metastases and tumor stage.
|
24114327 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NK4 gene therapy combined with cisplatin inhibits tumour growth and metastasis of squamous cell carcinoma.
|
21273587 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The inhibitory effect of IL-32γ on tumor growth was associated with the inhibition of constitutive activated nuclear transcription factor-κB (NF-κB) and of signal transducer and activator of transcription 3 (STAT3).
|
21423208 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, elevated levels of IL-32 transcripts in fine needle aspirates of tumor tissue have also been correlated with objective clinical responses in cancer patients receiving immunotherapy.
|
21760628 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Micro-RNA-205 induced the expression of tumor suppressor genes IL24 and IL32 at both the messenger RNA and protein levels.
|
20737563 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although successful tumor inhibition by NK4 gene expression in tumor models has been demonstrated, the effects of systemic NK4 gene introduction are yet to be addressed.
|
19438869 |
2009 |